Table 5.
PHAs (n=98) | CRs (n=157) | Others (n=102) a | Total (n=367) b |
|||||
---|---|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | n | (%) | |
Non-injector at baseline: | (59) | (60.2) | (102) | (65.0) | (53) | (52.0) | (220) | (59.9) |
Remained non-injector at 6-mo. | 58 | 98.3 c | 97 | 95.1 c | 50 | 94.3 c | 210 | 95.5 c |
Injector at baseline: | (39) | (39.8) | (55) | (35.0) | (49) | (48.0) | (147) | (40.1) |
Ceased all injection at follow-up | 18 | 46.2 d | 14 | 25.5 d | 22 | 49.9 d | 55 | 37.4 d |
Ceased or reduced injection rate | 30 | 76.9 d | 40 | 72.7 d | 37 | 75.5 d | 109 | 74.1 d |
Ceased or reduced sharing syringes or continued non-sharing |
38 | 97.4 e | 54 | 98.2 e | 45 | 91.8 e | 141 | 95.9 e |
Ceased or reduced sharing injection works or continued non-sharing |
36 | 97.3 e | 49 | 89.1 e | 44 | 89.8 e | 133 | 91.7 e |
Ceased or reduced sharing drug solutions or continued non-sharing |
35 | 94.6 e | 50 | 90.9 e | 46 | 93.9 e | 135 | 93.1 e |
Non-crack user at baseline: | (33) | (33.7) | (61) | (38.9) | (51) | (50.0) | (149) | (40.6) |
Remained non-crack user at follow-up | 31 | 93.9 f | 51 | 83.6 f | 39 | 76.5 f | 123 | 82.6 f |
Crack user at baseline: | (65) | (66.3) | (96) | (61.1) | (51) | (50.0) | (218) | (59.4) |
Ceased all crack use at follow-up | 28 | 43.1 g | 32 | 33.3 g | 18 | 35.3 g | 79 | 36.2 g |
Ceased or reduced rate of crack use | 47 | 72.3 g | 68 | 70.8 g | 31 | 60.8 g | 149 | 68.3 g |
Initiated or increased use of rubber tips | 29 | 70.7 h | 38 | 56.7 h | 21 | 63.6 h | 90 | 61.2 h |
Sexually active at baseline: | (75) | (76.5) | (112) | (72.3) | (72) | (70.6) | (266) | (72.9) |
Reduced number of sex partners | 38 | 50.7 i | 36 | 32.1 i | 34 | 47.2 i | 112 | 41.7 i |
Ceased or reduced all unprotected sex or continued no unprotected sex |
55 | 74.3 i | 81 | 73.6 i | 59 | 81.9 i | 200 | 76.3 i |
Ceased or reduced unprotected sex with primary partner |
55 | 75.3 i | 84 | 76.4 i | 59 | 83.1 i | 198 | 78.0 i |
Ceased or reduced unprotected sex with non-primary partner |
73 | 100.0 i | 103 | 93.6 i | 69 | 97.2 i | 251 | 96.5 i |
Ceased or reduced unprotected sex in exchange for money/drugs* |
73 | 100.0 i | 101 | 91.8 i | 67 | 94.4 i | 247 | 95.0 i |
Ceased all sexual activity | 18 | 24.0 i | 19 | 17.0 i | 18 | 25.0 i | 55 | 20.7 i |
Includes 76 CRs of all untrained PHAs (i.e., those who attended 0–4 training sessions) and 26 PHAs who never started the training; PHAs who attended 1–4 training sessions are excluded from this group.
Ten PHAs who attended only 1–4 sessions were included in the follow-up total.
Calculated as percent of participants who were non-injectors at baseline.
Calculated as percent of participants who were injectors at baseline.
Calculated as percent of participants who were injectors at either baseline or follow-up.
Calculated as percent of participants who were non-crack users at baseline.
Calculated as percent of participants who were crack users at baseline.
Calculated as percent of participants who smoked crack in the prior 6 months before both surveys.
Calculated as percent of participants who had sex in the last 30 days before the baseline surveys.
Differences in the comparison between PHAs and all other participants combined (CRs plus Others) were statistically significant (p < .05).